Piper Sandler Issues Positive Forecast for Masimo (NASDAQ:MASI) Stock Price

Masimo (NASDAQ:MASI) had its price target upped by Piper Sandler from $210.00 to $215.00 in a research report released on Wednesday,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.

A number of other equities research analysts have also recently commented on MASI. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday. Raymond James upped their price target on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Wells Fargo & Company boosted their price objective on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 target price (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Masimo has a consensus rating of “Moderate Buy” and an average target price of $194.80.

Masimo Price Performance

MASI opened at $190.34 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market capitalization of $10.19 billion, a price-to-earnings ratio of 131.27 and a beta of 1.02. The firm’s fifty day moving average price is $172.56 and its two-hundred day moving average price is $152.84. Masimo has a 1 year low of $101.61 and a 1 year high of $191.10.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. The firm had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. As a group, analysts anticipate that Masimo will post 4.1 earnings per share for the current fiscal year.

Institutional Trading of Masimo

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC raised its holdings in shares of Masimo by 19.8% during the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider’s stock valued at $1,338,509,000 after acquiring an additional 1,340,836 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Masimo by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider’s stock worth $758,182,000 after buying an additional 66,215 shares during the period. Capital Research Global Investors raised its stake in shares of Masimo by 80.5% in the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock worth $405,807,000 after buying an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Masimo by 119.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock worth $286,823,000 after acquiring an additional 943,001 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in shares of Masimo by 8.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,662,376 shares of the medical equipment provider’s stock worth $274,791,000 after purchasing an additional 135,888 shares during the period. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.